Tuesday, April 29, 2025

12:30 PM - 1:15 PM

M4

---

Details

Join us for an engaging discussion on the importance of quality of life when transitioning CML patients from 2L TKIs. Our expert speakers will explore the key considerations for treatment transition, the role of objective measures, and the impact of treatment changes to improve patient outcomes. Engage in an insightful exchange of experiences and best practices to enhance confidence in managing treatment transitions for CML patients. We will delve into the complexities of determining the appropriate timing for transitioning patients and provide strategies to enhance clinician confidence in making these crucial decisions. This promotional symposium is organised and funded by Novartis Pharmaceuticals UK, Ltd, intended for UK healthcare professionals only. Prescribing Information will be available at the meeting for all Novartis brands mentioned. The speakers have been offered an honorarium for their involvement in this programme. UK | March 2025 | FA-11352217-1 Adverse Event Reporting: Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report or alternatively email medinfo.uk@novartis.com or call 01276 698370

---

Speaker